What will the bank spend it on?
Challanges all over the place.
Anaemic performance seen in early 2017.
Leading pharma reports robust Q1 results.
Robust quarter projected.
New strategy works.
Just like Sergey Bubka.
Only Upstream EBITDA did not disappoint.
Risks all over the place.
Earnings report scheduled for next week.
Profit doubled, yet share price is falling.
Analysts expect major profit growth for Q416.
Robust profits in Q3.
Profit expectations beaten in Q3.